The proposed issuance will be within the limits already approved by the company’s Board of Directors at its meeting held on 28 July 2025, the company said in an exchange filing.
Torrent Pharma is the flagship company of the Torrent Group. It is ranked 7th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS) and Cosmo-Dermatology. It is a specialty-focused company with
76% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma companies in Brazil and Germany. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved.
On a consolidated basis, its revenue rose 14% year-on-year to Rs 3,302 crore, compared to Rs 2,889 crore in Q2 FY25. Gross profit stood at Rs 2,502 crore, up 13% YoY, maintaining a healthy margin of 76%.
The counter shed 0.34% to Rs 3,807.60 on the BSE.